Linfoma/leucemia de células T del adulto: Un desafío pendiente
DOI:
https://doi.org/10.35434/rcmhnaaa.2023.164.2189Palabras clave:
Virus Linfotrópico T Tipo 1 Humano, Leucemia-Linfoma de Células T del Adulto, Epidemiología, Protocolos AntineoplásicosResumen
El linfoma/leucemia de células T del adulto (ATLL) es una neoplasia de células T post tímicas de mal pronóstico y de difícil manejo. Se ha asociado etiológicamente al virus linfotrópico de células T humanas tipo 1 (HTLV-1), retrovirus que se ha identificado en zonas endémicas como Japón, África oriental, las islas del Caribe y Sudamérica. En el Perú, se estima que de 1 a 2% de la población es portadora del virus. El riesgo vital de desarrollar ATLL para un portador de HTLV-1 es de 5%. Dada la endemicidad de esta infección en nuestro medio y el pobre pronóstico del ATLL, resultan necesarias alternativas terapéuticas e intervenciones preventivas. En esta revisión, exploramos las características clínicas, epidemiológicas y las opciones de tratamiento del ATLL.
Descargas
Métricas
Citas
Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50:481–492.
Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77:7415–7419. DOI: 10.1073/pnas.77.12.7415
Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 1984; 81:2534–2537. DOI: 10.1073/pnas.81.8.2534
Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012; 3:388. DOI: 10.3389/fmicb.2012.00388
Alarcón JO. Friedman HB, Montano SM, Zunt JR, Holmes KK, Quinnan GV Jr. High Endemicity of Human T-cell Lymphotropic Virus Type 1 Among Pregnant Women in Peru. J Acquir Immune Defic Syndr. 2006; 42: 604-9. DOI: 10.1097/01.qai.0000221680.52563.d5
Zurita S, Costa C, Watts D, et al. Prevalence of human retroviral infection in Quillabamba and Cuzco, Peru: a new endemic area for human T cell lymphotropic virus type 1. Am J Trop Med Hyg 1997; 56: 561-5. DOI: 10.4269/ajtmh.1997.56.561
Sánchez-Palacios C, Gotuzzo E, Vandamme AM, Maldonado Y- Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV-I) infection among ethnically and geographically diverse Peruvian women. Int J Infect Dis 2003; 7: 132-7. DOI: 10.1016/s1201-9712(03)90009-9
Zunt J, Dezzutti C, Montano S, Thomas K, Alarcón J, Quijano E, et al. Cervical shedding of human t cell lymphotropic virus type i is associated with cervicitis. The J Infect Dis. (2002) 186:1669–72. DOI: 10.1086/345364 21.
Wignall F, Hyams K, Phillips I, Escamilla J, Tejada A, Li O, et al. Sexual transmission of human T-Iymphotropic virus type I in Peruvian prostitutes. J Med Virol. (1992) 38:44–8. DOI: 10.1002/jmv.1890380110 22.
La Rosa A, Zunt J, Peinado J, Lama J, Ton T, Suárez L, et al. Retroviral infection in peruvian men who have sex with men. Clin Infect Dis. (2009) 49:112–7. doi: 10.1086/599609 23. DOI: 10.1086/599609.
Stewart J, Heitzinger K, Pollett S, Calderón M, Alarcón J, Ton T, et al. The changing epidemiology of human T-cell lymphotropic virus type 1 infection in peruvian female sex workers, 1993–2010. Am J Trop Med Hyg. (2017) 96:373–79. doi: 10.4269/ajtmh.16-0014. DOI: 10.4269/ajtmh.16-0014
Ita F, Mayer E, Verdonck K, Gonzalez E, Clark D, Gotuzzo E. Human T-lymphotropic virus type 1 infection is frequent in rural communities of the southern Andes of Peru. Int J Infect Dis. 2014) 19:46–52. DOI: 10.1016/j.ijid.2013.10.005
Verdonck K, Gonzáles E, Van Dooren S, Vandamme A-M, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7: 266–81. DOI: 10.1016/S1473-3099(07)70081-6
Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989; 43: 250–53. DOI: 10.1002/ijc.2910430214.15. Gotuzzo E, Moody J, Verdonck K, Cabada MM, González E, Van Dooren S, et al. Frequent HTLV-1 infection in the offspring of Peruvian women with HTLV-1–associated myelopathy/tropical spastic paraparesis or strongyloidiasis. Rev Panam Salud Publica. 2007;22(4):223–30. DOI: 10.1590/s1020-49892007000900001
Barr RS, Drysdale SB, Boullier M, Lyall H, Cook L, Collins GP, Kelly DF, Phelan L and Taylor GP (2022) A Review of the Prevention of Mother-to-Child Transmission of Human T-Cell Lymphotrophic Virus Type 1 (HTLV-1) With a Proposed Management Algorithm. Front. Med. 9:941647. DOI: 10.3389/fmed.2022.941647
Iwanaga, M., Watanabe, T., Utsunomiya, A., Okayama, A., Uchimaru, K., Koh, K. R., et al. (2010). Human T-cell leukemia virus type I (HTLV-I) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116, 1211–1219. DOI: 10.1182/blood-2009-12- 257410
Wolfa S, Vercruyssen M, Cook L. HTLV-1-related adult T-cell leukemia/lymphoma: insights in early detection and management. Curr Opin Oncol 2022, 34:446–453 DOI:10.1097/CCO.0000000000000883
Alvarez C, Gotuzzo E, Vandamme A-M and Verdonck K (2016) Family Aggregation of Human T-Lymphotropic Virus 1-Associated Diseases: A Systematic Review. Front. Microbiol. 7:1674. DOI: 10.3389/fmicb.2016.0167420. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol 1991; 79: 428–37. DOI: 10.1111/j.1365-2141.1991.tb08051.x
Tsukasaki K, Imaizumi Y, Tokura Y, et al. Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma. J Dermatol 2014; 41:26–28. DOI: 10.1111/1346-8138.12374
Bittencourt A, Carvalho-Andrade A, Requiao C, Arruda M, Araújo I. Prolonged lymphocytosis as the first manifestation of Hodgkin-like adult T-cell leukemia/lymphoma. Braz J Infect Dis. 2017 Jan-Feb; 21(1): 119–122. DOI: 10.1016/j.bjid.2016.09.00523. Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30(14):1635–40. DOI: 10.1200/JCO.2011.38.2101
Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014;166(5):739–48. DOI: 10.1111/bjh.1296225. Fuji Yamaguchi T, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, et al. Development of a modifed prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017;102(7):1258–65. DOI: 10.3324/haematol.2017.16499626. Kataoka K, Iwanaga M, Yasunaga JI, Nagata Y, Kitanaka A, Kameda T, et al. Prognostic relevance of integrated genetic profling in adult T-cell leukemia/lymphoma. Blood. 2018;131(2):215–25. DOI: 10.1182/blood-2017-01-76187427. Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, Utsunomiya A, et al. Prognostic index for chronic- and smoldering type adult T-cell leukemia-lymphoma. Blood. 2017;130(1):39–47. DOI: 10.1182/blood-2017-01-757542
Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):54. DOI: 10.1200/JCO.2007.11.9958
Toyoda K, Tsukasaki K, Machida R, Kadota T, Fukushima T, Ishitsuka K, et al. Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801. Br J Haematol. 2019;186(3):440–7. DOI: 10.1111/bjh.15950
Fuji S, Yamaguchi T, Inoue Y, Utsunomiya A, Moriuchi Y, Owatari S, et al. VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis. Bone Marrow Transplant. 2019;54(9):1399–405. DOI: 10.1038/s41409-019-0446-z
Toriyama E, Imaizumi Y, Taniguchi H, Taguchi J, Nakashima J, Itonaga H, Sato S, Ando K, Sawayama Y, Hata T, Fukushima T, Miyazaki Y. EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma. Int J Hematol. 2018 Aug;108(2):167-175. DOI: 10.1007/s12185-018-2455-x
Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177–83. DOI: 10.1200/JCO.2010.28.0669
Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol. 2011;29(35):4696–701. DOI: 10.1200/JCO.2011.35.5578
Katsuya H. Current and emerging therapeutic strategies in adult T-cell leukemia-lymphoma. Int J Hematol. 2023 Apr;117(4):512-522. DOI: 10.1007/s12185-023-03572-4
Tanaka T, Nakamae H, Ito A, Fuji S, Hirose A, Eto T, et al. A phase I/II multicenter Trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia/lymphoma. Transplant Cell Ther. 2021;27(11):928-e7. DOI: 10.1016/j.jtct.2021.07.010
Sawada Y, Hino R, Hama K, Ohmori S, Fueki H, Yamada S, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood. 2011;117(15):3961–7. DOI: 10.1182/blood-2010-11-316794
Katsuya H. Current and emerging therapeutic strategies in adult T-cell leukemia-lymphoma. Int J Hematol. 2023 Apr;117(4):512-522. DOI: 10.1007/s12185-023-03572-4
Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42. DOI: 10.1200/JCO.2011.37.3472
Sakamoto Y, Ishida T, Masaki A, Murase T, Yonekura K, Tashiro Y, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood. 2018;132(7):758–61. DOI: 10.1182/blood-2018-02-835991
Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with signifcantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426–33. DOI: 10.1200/JCO.2016.67.8250
Campuzano-Zuluaga G, Pimentel A, Chapman-Fredricks JR, Ramos JC. Differential CD30 expression in adult T-cell leukemia-lymphoma subtypes. Retrovirology. 2014 Jan 7;11(Suppl 1):P129.
Baba Y, Sakai H, Kabasawa N, Harada H. Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy. Intern Med. 2023 Feb 15;62(4):613-616. DOI: 10.2169/internalmedicine.9812-22
Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34(34):4086–93. DOI: 10.1200/JCO.2016.67.7732
Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38–51. DOI: 10.1038/nrc1779
Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/ lymphoma: phase IIb results. Cancer Sci. 2022;113(8):2778–87. DOI: 10.1111/cas.15431
Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research. Clin Cancer Res. 2014;20(20):5217–25. DOI: 10.1158/1078-0432.CCR-14-0572
Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–14. DOI: 10.1016/j.cell.2015.03.030
Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378(20):1947–8. DOI: 10.1056/NEJMc180318149. Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, et al. An open-label, single-arm, phase 2 trial of valemetostat in relapsed or refractory adult T-cell leukemia/lymphoma. Blood 2023; 141(10):1159-1168. DOI: 10.1182/blood.202201686250. Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29(8):2321-37.e7. DOI: 10.1016/j.celrep.2019.10.083
Descargas
Publicado
Cómo citar
Número
Sección
Categorías
Licencia
Derechos de autor 2024 Carolina Álvarez, Brady Beltran
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
